skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
HLA-A*2402-Restricted Multipeptide Vaccine S-488410 (Code C101893)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: HLA-A*2402-Restricted Multipeptide Vaccine S-488410

Definition: A cancer vaccine composed of HLA-*2402-restricted epitopic peptides derived from three cancer/testis (CT) antigens, with potential antineoplastic activity. Upon subcutaneous administration, HLA-A*2402-restricted multipeptide vaccine S-488410 may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing these CT antigens. CT antigens, normally expressed only in germ cells of the testis, are overexpressed in a wide variety of human cancers.

Label: HLA-A*2402-Restricted Multipeptide Vaccine S-488410

NCI Thesaurus Code: C101893 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL436276  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
HLA-A*2402-Restricted Multipeptide Vaccine S-488410

External Source Codes: 
PDQ Closed Trial Search ID 733798
PDQ Open Trial Search ID 733798 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C101893
Semantic_Type Immunologic Factor
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom